Skip to main content
. 2021 Feb 8;39(12):1329–1338. doi: 10.1200/JCO.20.01375

FIG 2.

FIG 2.

Kaplan-Meier estimate of (A) PFS for all patients, n = 280 and (B) OS for all patients, n = 280. OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2CHOP, lenalidomide plus R-CHOP.